General Information of Drug (ID: DM4GSHY)

Drug Name
KA-10X Drug Info
Synonyms KA-101; KA-102; G3BP antagonist peptides (cancer), Wuhan KatyGen Pharmaceuticals; RasGAP/RasGAP binding protein antagonist peptides (cancer), Wuhan Katygen Pharmaceuticals
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Investigative [1]
Cross-matching ID
TTD Drug ID
DM4GSHY

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug(s) Targeting GTPase NRas (NRAS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Salirasib DMRSU4X Lung cancer 2C25.0 Phase 2 [2]
Mutant ras vaccine DMM6KZR Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
GI-4000 DMTY4PG Colorectal cancer 2B91.Z Phase 2 [4]
Reovirus DMQ73AY Head and neck cancer 2D42 Phase 2 [5]
Perillyl alcohol DMFWC3O Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 2 [1]
APC-300 DMNIEHV Prostate cancer 2C82.0 Investigative [1]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
GTPase NRas (NRAS) TTW2R9X RASN_HUMAN Antagonist [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2823).
2 The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Methods Enzymol. 2008;439:467-89.
3 The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J Transl Med. 2014 Feb 24;12:55.
4 Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation. Clin Lung Cancer. 2014 Nov;15(6):405-10.
5 Reovirus (Reolysin) as a potential therapy for malignant peripheral nerve sheath tumors.